Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) EBITDA Margin: 2024-2025

Historic EBITDA Margin for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Sep 2025 value amounting to -211.11%.

  • Monte Rosa Therapeutics' EBITDA Margin rose 4400.00% to -211.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 11.03%, marking a year-over-year change of. This contributed to the annual value of -96.97% for FY2024, which is N/A change from last year.
  • Monte Rosa Therapeutics' EBITDA Margin amounted to -211.11% in Q3 2025, which was down 296.84% from -53.20% recorded in Q2 2025.
  • Monte Rosa Therapeutics' EBITDA Margin's 5-year high stood at 55.24% during Q1 2025, with a 5-year trough of -3,001.60% in Q1 2024.
  • In the last 2 years, Monte Rosa Therapeutics' EBITDA Margin had a median value of -211.11% in 2025 and averaged -584.35%.
  • Data for Monte Rosa Therapeutics' EBITDA Margin shows a peak YoY spiked of 305,683bps (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Monte Rosa Therapeutics' EBITDA Margin stood at 20.45% in 2024, then skyrocketed by 4,400bps to -211.11% in 2025.
  • Its EBITDA Margin was -211.11% in Q3 2025, compared to -53.20% in Q2 2025 and 55.24% in Q1 2025.